Compare Citius Pharmaceuticals Inc (CTXR) vs Vertiv Holdings Co (VRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Vertiv Holdings Co — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while Vertiv Holdings Co trades at $305 (market cap $116.61B). The key difference: Vertiv Holdings Co is far larger — about 7965.2× Citius Pharmaceuticals Inc's market cap, and Vertiv Holdings Co pays a 0.08% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | VRT | |
|---|---|---|
Market Cap | $14.64M | $116.61B |
Sector | Health | Technology |
52-Week High | $1.82 | $376.23 |
52-Week Low | $0.53 | $121.82 |
Enterprise Value | $10.86M | $117.37B |
Dividend Yield | — | 0.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
Vertiv Holdings (VRT) trades at $305.87, down 4.07% today, amid strong fundamental performance with consistent earnings beats and robust AI-driven demand. The stock shows neutral technical signals with support at $300 and resistance at $314, while maintaining impressive profitability metrics including 45.1% ROE and 14.37% net margin. Recent news highlights Vertiv's $15 billion order backlog and expansion in Malaysia to capitalize on AI infrastructure growth.
The outlook remains positive with 94.7% analyst buy ratings and a $407.45 consensus target, representing 33% upside potential. Key risks include premium valuation multiples (P/E 76.28) and competitive pressures, but strong cash flow generation and AI infrastructure tailwinds support continued growth momentum through 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Vertiv Holdings Co
Vertiv is a global leader in critical digital infrastructure, providing essential power, cooling, and IT management solutions for data centers, communication networks, and industrial facilities. As the primary provider of advanced thermal management and liquid cooling systems, Vertiv is a central player in the AI revolution, enabling the extreme density and power requirements of next-generation GPU-driven computing.
Read more on VRT →
